MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.030
-0.390
-8.82%
Opening 15:29 01/27 EST
OPEN
4.140
PREV CLOSE
4.420
HIGH
4.370
LOW
4.010
VOLUME
202.31K
TURNOVER
--
52 WEEK HIGH
38.75
52 WEEK LOW
2.580
MARKET CAP
26.78M
P/E (TTM)
-11.5905
1D
5D
1M
3M
1Y
5Y
BRIEF-Neurometrix Reports Q4 And Full Year 2021 Financial Results
reuters.com · 7h ago
NeuroMetrix reports Q4 results
NeuroMetrix press release (NASDAQ:NURO): Q4 net loss of $1M Revenue of $1.82M (+0.6% Y/Y).
Seekingalpha · 8h ago
-- Earnings Flash (NURO) NEUROMETRIX Posts Q4 Revenue $1.8M
MT Newswires · 13h ago
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022. The Company will host a c...
GlobeNewswire · 01/20 17:10
CLFD, NURO and PIXY among mid-day movers
Gainers: Zogenix (NASDAQ:ZGNX) +67%. Vivos Therapeutics (NASDAQ:VVOS) +48%. G Medical Innovations (NASDAQ:GMVD) +46%. ShiftPixy (NASDAQ:PIXY) +31%. Splash Beverage (NYSE:SBEV) +28%. New Pacific (NYSE:NEWP) +18%. Gamida Cell (NASDAQ:GMDA) +18%. Vaxxinity (N...
Seekingalpha · 01/19 17:38
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion.
Benzinga · 01/19 17:00
Zogenix, Vivos lead healthcare gainers; Cardiff Oncology, Yumanity among losers
Gainers: Zogenix (NASDAQ:ZGNX) +68%. Vivos Therapeutics (NASDAQ:VVOS) +33%. Gamida Cell (NASDAQ:GMDA) +21%. Vaxxinity (NASDAQ:VAXX) +13%. Renalytix (NASDAQ:RNLX) +11%. Losers: Cardiff Oncology (NASDAQ:CRDF) -24%. Yumanity Therapeutics (NASDAQ:YMTX) -17%. O...
Seekingalpha · 01/19 15:05
SLI, YMTX and NURO among pre market losers
Yumanity Therapeutics (NASDAQ:YMTX) -12% reports partial clinical hold by U.S. FDA on multidose clinical trials for YTX-7739. Cardiff Oncology (NASDAQ:CRDF) -12% posts new data for lead program in colorectal cancer. Ensysce Biosciences (NASDAQ:ENSC) -12%.
Seekingalpha · 01/19 13:19
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NURO. Analyze the recent business situations of NeuroMetrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
High50.00
Average50.00
Low50.00
Current 4.050
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 35
Institutional Holdings: 799.89K
% Owned: 12.04%
Shares Outstanding: 6.65M
TypeInstitutionsShares
Increased
6
374.29K
New
11
133.68K
Decreased
4
95.28K
Sold Out
4
58.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.92%
Healthcare Equipment & Supplies
-0.86%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Shai Gozani
Chief Financial Officer/Senior Vice President/Treasurer
Thomas Higgins
Independent Director
David Goodman
Independent Director
Nancy Katz
Independent Director
David Van Avermaete
Declaration Date
Dividend Per Share
Ex-Div Date
03/14/2007
Dividend USD 0.15
03/28/2007
About NURO
NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.